ClinicalTrials.gg

Program

petosemtamab

Also written as “Petosemtamab”, “MCLA-158” and “MCLA-158 + Pembrolizumab”.

Its studies are mostly in Colorectal Neoplasms · Squamous Cell Carcinoma of Head and Neck · Lung Neoplasms, led by Genmab.

Furthest: phase 3, since Jul 3, 20246 company-led studies, 5 open or runningNext primary completion: Jan 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genmab65 open or runningphase 3since Jul 3, 2024Apr 4, 2018Jan 2028phase 3 · NCT06525220

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 4, 2018First study: phase 2 study in Colorectal NeoplasmsFirst studyNCT03526835 · 560 planned · United States, Belgium, France and more
  2. Jul 3, 20242 phase 3 studies in Squamous Cell Carcinoma of Head and NeckNCT06496178, NCT06525220
  3. Jan 16, 2026Phase 2 study in Lung NeoplasmsNCT07353957 · United States, Australia, France and more
  4. Jul 9, 2026Phase 3 study in Left-sided Colorectal CancerNCT07702032 · 960 planned · United States, Australia, Puerto Rico
  5. Aug 13, 2026Phase 3 study in Colorectal NeoplasmsNCT07775287 · 600 planned · United States, Puerto Rico

Ahead

  1. Jan 2028Primary completion: phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT06525220
  2. Feb 2028Primary completion: phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT06496178
  3. May 2028Primary completion: phase 2 study in Colorectal NeoplasmsNCT03526835
  4. Mar 30, 2029Primary completion: phase 3 study in Colorectal NeoplasmsNCT07775287

TargetBeta

EGFR →LGR5 →read by rule
“An immunoglobulin G1 (IgG1) bispecific antibody targeting both epidermal growth factor receptor (EGFR; HER1; ErbB1) and leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), ”NCIt, by rule

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07775287Colorectal Neoplasms · United States, Puerto Rico3RecruitingMar 30, 2029600
NCT07702032Left-sided Colorectal Cancer · United States, Australia, Puerto Rico3RecruitingJul 2029960
NCT07353957Lung Neoplasms · United States, Australia, France and more2WithdrawnMay 31, 20280
NCT06525220Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more3Active, not recruitingJan 2028699
NCT06496178Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more3Active, not recruitingFeb 2028621
NCT03526835Colorectal Neoplasms · United States, Belgium, France and more2RecruitingMay 2028560

How it is read

Names in the registry

  • “Petosemtamab”, 4 entries
  • “MCLA-158”, 1 entry
  • “MCLA-158 + Pembrolizumab”, 1 entry
  • “MCLA-158 + FOLFIRI”, 1 entry
  • “MCLA-158 + FOLFOX”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.